ALPHAMAB ONCOLOGY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.67 HKD | -3.31% |
|
-11.89% | -29.67% |
| 05-02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
| 04-10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 577M | - | |||||
| 63.85B | - | |||||
| 41.83B | ||||||
| 40.65B | ||||||
| 27.12B | ||||||
| 26.52B |
- Stock Market
- Equities
- 9966 Stock
- Charts Alphamab Oncology
- Sector Chart
